Less Ads, More Data, More Tools Register for FREE

Pin to quick picksUnicorn Asset Management Regulatory News (UAV)

Share Price Information for Unicorn Asset Management (UAV)

Share Price is delayed by 15 minutes
Get Live Data
70.00    0.00 (0.00%)
Bid:
67.00
Ask:
73.00
Spread: 6.00 (8.955%)
Market Cap: £180.27m
UAV Live PriceLast checked at - London Stock Exchange

Intraday Unicorn Asset Management Share Chart

Voluntary Interim Management Statement

14 Jan 2019 13:28

RNS Number : 0389N
Unicorn AIM VCT PLC
14 January 2019
 

Unicorn AIM VCT plc ("the Company")

Interim Management Statement 

For the period from 1 October 2018 to 31 December 2018

 

Introduction

This voluntary Interim Management Statement (IMS) covers the three month period ended 31 December 2018, together with relevant information up to the date of publication. 

 

Investment Objective

The Company's objective is to provide Shareholders with an attractive return from a diversified portfolio of investments, predominantly in the shares of AIM quoted companies, by maintaining a steady flow of dividend distributions to Shareholders from the income as well as capital gains generated by the portfolio.

 

It is also the objective that the Company should continue to qualify as a Venture Capital Trust, so that Shareholders benefit from the taxation advantages that this brings. To achieve this at least 70% (80% for accounting periods commencing after 5 April 2019) of the Company's total assets are to be invested in qualifying investments of which 70% by VCT value (30% in respect of investments made before 6 April 2018 from funds raised before 6 April 2011) must be in ordinary shares which carry no preferential rights (save as permitted under VCT rules) to dividends or return of capital and no rights to redemption.

 

Performance

The period under review has been an extremely challenging one for UK equity markets. Uncertainty surrounding the outcome of Brexit negotiations, an escalating trade war between the US and China, concerns over a slowdown in the Chinese economy and deteriorating financial results from some of the world's most highly valued quoted companies, led to a rapid reversal in investor sentiment. In the UK, a combination of weak consumer spending, over-supply in the retail sector and a number of high profile corporate insolvencies exacerbated the sharp sell-off in equities. The short term health of the UK economy appears dependent on securing a successful deal with the European Union, which, in itself, now seems in doubt.

 

In the past three months, the largest declines in value have generally been experienced by smaller quoted companies. In total return terms, since the start of October 2018, the FTSE AIM All-Share Index has fallen by 21.5%, while the Numis Smaller Companies Index (including AIM) has declined by 14.6%. The FTSE 250 Index fell by 13.3% over the same period, while the FTSE 100 Index declined by 9.6%.

 

Your Company has not been immune from the wider market turmoil. Although performance in the period was not specifically impacted by profit warnings from any of our investee companies, the value of the portfolio as a whole nonetheless experienced a meaningful decline.

 

In the three month period ended 31 December 2018, Net Asset Value fell from 171.8 pence per share at the start of the period to 141.7 pence per share as at 31 December 2018, a decline of 17.5%. Of the 79 VCT qualifying investments held in the portfolio, the majority recorded share price declines during the period under review. Of these, eight investments generated unrealised capital losses in excess of £1 million each. The performance of the non-qualifying investments was similarly impacted by the general malaise in equity markets during the period under review.

 

At 31 December 2018, an estimated 80.5% of total assets were invested in VCT qualifying companies.

 

Material Transactions

During the period under review, six VCT qualifying investments were made at a total cost of nearly £3 million. Of these investments, two were in businesses new to the portfolio, while four were in the form of follow-on funding.

In aggregate, almost £2.5 million was raised from the partial disposal of a number of holdings during the period. The purpose of such disposals is threefold; to ensure stock specific risk is contained, to lock in capital profits for future distribution to Shareholders via dividend payments and to help manage liquidity requirements. Two further investments; Communisis and Sinclair Pharma, were acquired by trade buyers during the period realising total proceeds of £2.3 million and a capital gain on investment of £0.5m. A holding in Science Group was also fully realised, raising £1.0 million and crystallising a capital gain of £0.8m.

Top Ten VCT Qualifying Holdings as at 31 December 2018

Stock

% of fund

Abcam

8.6

Tracsis

5.9

Mattioli Woods

3.9

Hasgrove

3.9

Interactive Investor

3.8

Anpario

3.7

City Pub Group

3.5

MaxCyte

3.1

Cohort

2.7

Tristel

2.4

Total

41.5%

 

Share Buy-Backs

During the period from 1 October 2018 to 31 December 2018, the Company bought back 407,205 of its own Ordinary Shares for cancellation, at an average price of 129.6 pence per share including costs. As at 31 December 2018, there were 116,818,843 Ordinary Shares in issue.

 

 

 

 

Dividends

The Board has recommended a final dividend of 3.5 pence per share for the financial year ended 30 September 2018. The proposed dividend was approved by Shareholders at the Company's Annual General Meeting, which was held on 10 January 2019, and will be paid on 1 February 2019 to Shareholders on the register on 11 January 2019. Total dividends paid in respect of the financial year ended 30 September 2018, will therefore amount to 6.5 pence per share (2017: 6.5 pence per share).

 

Material Events

On 20 December 2018, the Directors announced that they intend to launch an offer for subscription to raise £15 million (with an over-allotment facility to raise up to a further £10 million) through the issue of new ordinary shares ("the Offer"). The prospectus, which will contain the full details and terms and conditions of the Offer, is expected to be available at the end of January 2019.

 

There were no other material events during the period from 1 October 2018 to 31 December 2018.

 

We remain confident that we have a well diversified portfolio of interesting companies of varying maturities. While stock markets may well remain volatile in the short term, we are cautiously optimistic that, once the outcome of the Brexit negotiations becomes clear, the portfolio performance should become more positive.

 

Chris Hutchinson

Unicorn Asset Management

Investment Manager

 

14 January 2019

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCZMGMMFDKGLZM
Date   Source Headline
5th Jun 20261:06 pmRNSNet Asset Value(s)
1st Jun 202610:50 amRNSTotal Voting Rights
20th May 202610:06 amRNSIssue of Equity
15th May 202610:33 amRNSAppointment of Director
6th May 20262:01 pmRNSNet Asset Value(s)
1st May 202610:07 amRNSTotal Voting Rights
1st Apr 20264:20 pmRNSNet Asset Value(s)
1st Apr 20268:22 amRNSTotal Voting Rights
12th Mar 20267:00 amRNSOffer for Subscription Update - Overallotment
10th Mar 20265:10 pmRNSTransaction in Own Shares
10th Mar 20265:10 pmRNSTransaction in Own Shares
6th Mar 20267:00 amRNSIssue of Equity
5th Mar 20262:12 pmRNSIssue of Equity
4th Mar 20265:49 pmRNSNet Asset Value(s)
3rd Mar 20262:17 pmRNSNet Asset Value(s)
2nd Mar 20267:00 amRNSTotal Voting Rights
18th Feb 20264:23 pmRNSTransaction in Own Shares
13th Feb 20267:00 amRNSIssue of Equity
6th Feb 202612:01 pmRNSNet Asset Value(s)
4th Feb 20264:34 pmRNSResult of AGM
26th Jan 20264:19 pmRNSOffer for Subscription and Issue of Offer Document
15th Jan 20263:57 pmRNSDividend Declaration
14th Jan 20262:33 pmRNSNet Asset Value(s)
22nd Dec 20254:28 pmRNSPortfolio Update
22nd Dec 20254:28 pmRNSPortfolio Update
10th Dec 20252:24 pmRNSNet Asset Value(s)
5th Dec 20257:12 amRNSDirector Declaration
5th Dec 20257:00 amRNSFinal Results
28th Nov 20251:34 pmRNSPortfolio Update
27th Nov 20257:00 amRNSStatement re Intention to Launch an Offer
6th Nov 20257:00 amRNSNet Asset Value(s)
13th Oct 20254:28 pmRNSNet Asset Value(s)
2nd Sep 202511:22 amRNSNet Asset Value(s)
1st Sep 20259:30 amRNSTotal Voting Rights
14th Aug 20254:57 pmRNSTransaction in Own Shares
12th Aug 20254:13 pmRNSDirector/PDMR Shareholding
12th Aug 202510:27 amRNSIssue of Equity under DRIS
6th Aug 202511:08 amRNSNet Asset Value(s)
1st Aug 20259:02 amRNSTotal Voting Rights
22nd Jul 202510:03 amRNSTransaction in Own Shares
4th Jul 202511:55 amRNSNet Asset Value(s)
1st Jul 20259:33 amRNSTotal Voting Rights
18th Jun 20254:44 pmRNSTransaction in Own Shares
3rd Jun 20251:57 pmRNSNet Asset Value(s)
20th May 20257:00 amRNSHalf-year Report
6th May 20253:24 pmRNSNet Asset Value(s)
15th Apr 20259:48 amRNSIssue of Equity
15th Apr 20257:00 amRNSNet Asset Value(s)
4th Apr 20257:00 amRNSIssue of Equity
1st Apr 20254:23 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.